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Abstract. We describe a defective HeLa nuclear extract which is particularly 
deficient in step 2 of splicing reaction. With this extract we have studied the 
conservation of a second-step activity from yeast to human cells. We 
detected a S. cerevisiae second-step splicing activity that allows restoration 
of step 2 of the defective HeLa nuclear extract, which indicates that yeast 
purified fraction has a second-step activity that is conserved from yeast to 
human cells. The activity is a yeast UsnRNP protein(s) since it is purified 
with anti-tri-methyl-guanosine by immunoaffinity columns. 
 
The splicing reaction of nuclear pre-mRNAs has a similar mechanism 
in yeast and mammalian cells (1). Human spliceosomal factors can be 
divided in three categories: 1) UsnRNPs; 2) SR proteins and 3) other 
polypeptides (2). In yeast no SR proteins have been detected (3). UsnRNPs 
are the most conserved factors from yeast to mammalian cells, consisting of 
complexes of U1, U2, U4/U6 and U5 snRNAs with a known set of proteins 
(4). In this study we attempt to determine which second-step activities are 
conserved from yeast to human cells. We used an in vitro complementation 
in which yeast spliceosomal proteins were added to a HeLa cell nuclear 
extract defective for the second step reaction. The study focuses on a 
second-step activity present in a yeast UsnRNP splicing particle, which is 
conserved across species. Yeast UsnRNPs were chosen because a) they are 
easy to purify with immunoaffinity columns and b) many yeast second-step 
factors have been cloned and can be easily purified from recombinant cells. 
It is thus possible to perform further studies to improve our knowledge of 
second-step splicing activities. 
UsnRNP splicing factors from yeast source contain a second-step 
activity that complements in vitro the second-step splicing reaction of the 
defective mammalian system. 
 
MATERIALS AND METHODS 
 
HeLa nuclear extracts defective for the second step (hNE-2nd). We 
obtained nuclear HeLa extracts from frozen cells defective for the second 
step of the splicing reaction. Frozen HeLa cells, provided by 4C Company 
(Computer Cell Culture Center S.A., Mons, Belgium) were used for the 
preparation of extracts. The cells were stored at -80 ºC for 6–8 months. The 
method of Dignam et al. (5) was modified on the following steps: a) the 
cells were defrosted in one volume of on the following steps: a) the cells 
were defrosted in one volume of PBS buffer (20 mM potassium phosphate 
pH 7.3, 130 mM NaCl) at 37 ºC (this temperature is only used to thaw the 
cells; all other steps were performed at 4 ºC); b) during the swell step in 
buffer A (see composition of this buffer in ref. 5), cells were allowed to swell 
on ice for 30 min. The swollen cells were collected by centrifugation as 
stated and resuspended in two cell pellet volumes (i.e., the volume before 
the initial wash with buffer A) of buffer A and lysed by 15 strokes of a glass 
Dounce homogenizer (tight pestle); c) the extraction of the nuclei in buffer 
C (see composition of this buffer in ref. 5), which was done by 15 strokes 
(instead of 10 strokes) of a glass Dounce homogenizer. In summary, the 
main changes on the procedure are: use of frozen cells stored at -80 ºC for 
6–8 months; longer incubation in hypotonic buffer and increase of the 
stroke number in all Douncer homogenizer steps. Frozen HeLa cells swelled 
little in hypotonic buffer A. This defect provokes that few protein is 
extracted from the total pellets obtained, which is mainly composed by not 
swollen and unbroken cells (this observation was followed under microscope 
and protein determination). We therefore decided to modify this swelling 
step to obtain a higher yield of nuclei.  
One of these extracts is shown in Fig. 1. Lane 1 corresponds to the 
splicing reaction in a fully active nuclear extract (from HeLa cells harvested 
from cell culture media and immediately used -referred as fresh cells-to 
obtain nuclear extracts), in which the lariat-exon2 and exon1 intermediate, 
and the exon1-exon2 product are clearly shown. Lanes 2–5 in Fig. 1 show 
the splicing reaction for HeLa cell nuclear extract defective for the second 
step (hNE-2nd); the control sample has no ATP (lane 2) and the other 
samples have increasing percentages of hNE-2nd (between 20–60% of 
nuclear extract in lanes 3–5). Lanes 3–5 show that the first step of the 
splicing reaction is accomplished in these extracts (lariat still bound to 
exon2), but not the second step (absence of the exon1-exon2 product in 
lanes 3–5). The RNA bands shown in the figure 1 were characterized and 
correspond to the wild type intermediates. Three different hNE-2nd were 
obtained with this method, and the experiments here shown were repeated 
with these three extracts with similar results. 
 
Purification of yeast UsnRNPs (yUsnRNPs). UsnRNPs were purified 
from total yeast extracts (prepared as previously described, (6)) passed 
through anti-m3G immunoaffinity columns containing either the anti-m3G 
monoclonal antibody called Ab-1 (Oncogene Science, ref 7). The 
immunoaffinity purification of the yeast UsnRNPs from total yeast extract 
was described by Fabrizio, P. et al. (6). yUsnRNPs were concentrated either 
by PEG 40.000 or by centrifugation through 3 kDa salt-cut membranes and 
finally dialyzed against PBS. The yeast strain used to obtain the total yeast 
extract was EJ101 (generous gift from Dr. M. Rosbash).  
 
Splicing reactions. Splicing conditions were those previously published 
(8).  
 
 
 
 
 
FIG. 1. Splicing reaction of defective and fully active extracts with β-globin pre-
mRNA. The defective HeLa nuclear extract (hNE-2nd), which only performed the first 
step of the splicing reaction, was prepared as described in Material and Methods. 
The fully active extract was prepared as previously described (5). Lanes: 1, fully 
active extract (40%) with ATP; lane 2, hNE-2nd (40%) without ATP; lanes 3–5, hNE-
2nd with ATP using 20%, 40% and 60% of hNE-2nd, respectively. The total time of 
the splicing reaction was 90 min.  
 
RESULTS AND DISCUSSION  
 
Extracts depleted for second-step factors are suitable to perform 
complementation studies with functional factors, particularly with those 
from other sources. This study focuses on one group of spliceosomal 
factors: the yeast UsnRNPs, which were purified in a native form by binding 
to anti-m3G immunoaffinity columns and elution with competitor nucleoside 
(6). The rationale for using yeast UsnRNPs was discussed in the 
introduction. hNE-2nd extracts were complemented with purified yUsnRNPs. 
In these complementation experiments, yUsnRNPs were added to hNE-2nd at 
different times for 90 min following initiation of the splicing reaction. The 
results are shown in Fig. 2A with the β-globin pre-mRNA. Lanes 1–3 
corresponds to splicing reactions with a fully active extract; two duplicate 
reactions with ATP (lanes 2 and 3) and one control reaction without ATP 
(lane 1). Lanes 4–10 are splicing reactions with hNE-2nd complemented 
(lanes 6–10) with 1 µg of yUsnRNPs at 0, 15, 30, 45 and 60 min after the 
initiation of the splicing reaction respectively, while lanes 4 and 5 are 
negative controls without yUsnRNPs (and without and with ATP, 
respectively). Lane 5 shows that only the first step is completed in hNE-2nd 
splicing reaction, as demonstrated by the presence of the branched intron-
exon2 intermediate and by the absence of the debranched intron and 
exon1-exon2 products, this exon1-exon2 band was characterized and it 
corresponded to the same wild-type product shown in Fig. 2A, lane 2 and 3. 
40% of extract and rabbit β-globin pre-mRNA was used in all these splicing 
reactions. Out of this figure we can extract the following observations. a) 
Lanes 7 and 8 of Fig. 2A indicate that when 1 µg of purified yUsnRNPs was 
added to hNE-2nd 15 or 30 min after the initiation of the reaction, the second 
step was completed (note exon1-exon2 and debranched intron in lanes 7 
and 8). The second step was not completed when buffer was added instead 
of yUsnRNPs (Fig. 2A lane 5) or when yUsnRNPs were added 0, 45 or 60 
min after the initiation of the splicing reaction (the second step is indicated 
by the presence of exon1-exon2, which does not appear in lanes 4–6, 9 or 
10).  
 
 
 
FIG. 2. Complementation of the hNE-2nd with yUsnRNPs by time-course 
performance. Panel B shows a longer time exposition of the upper part of the gel 
shown in Panel A. All the reactions, which were done with β-globin pre-mRNA, were 
incubated for a total time of 90 min and with 40% of extract. Lanes 1–3 are splicing 
reaction control samples with fully active extract and ATP (lanes 2 and 3, duplicate 
reactions) and without ATP (lane 1). Lanes 4 and 5 are splicing reaction control 
samples of hNE-2nd without and with ATP, respectively. In lanes 6–10, the splicing 
reactions were complemented with 1 µg of yUsnRNPs at 0, 15, 30, 45 and 60 min, 
respectively, after the beginning of the reaction and allowed to proceed until a total 
incubation time of 90 min. The region indicated with a bracket and an asterisk 
corresponds to the additional intermediates obtained in splicing reactions performed 
with hNE-2nd; they are better shown in the upper part of panel B. Band 1 in panel B 
turned out to be the wild-type lariat which contains the wild-type 5* splice-site and 
branch-point. Band 2 in panel B could not clearly be characterized.  
 
This complementation depends on yUsnRNPs, since other protein 
fractions (e.g. DEAE I and II from Lindsey et al. see ref (9)) or buffers 
(buffer A or D from Dignam et al., see ref. (5)) did not complement hNE-2nd 
to complete the second step products. An increase of the amount of hNE-2nd 
(60–90% of extract during the splicing reaction; 60% extract is shown in 
Fig. 1, lane 5) did not allow the completion of the second step. The addition 
of 1 µg of total protein of fully active nuclear extract from yeast was not 
enough to complete the second step reaction (not shown). This indicates 
that the complementation to the second-step product is dependent on the 
presence of purified yUsnRNPs and it is not dependent on the presence of 
any protein.  
We conclude that there is a conservation of a second-step activity 
from yeast to human cells that belongs to the UsnRNP family. This activity 
is named ySSA (yeast second-step activity), to distinguish it from the 
previously described SSF1 yeast factor (11).  
 
Splicing reactions in hNE-2nd showed additional bands near the 
branched intron which are marked with asterisks in Figs. 2A and 2B (the 
upper half of Fig. 2A, containing the lariats, was exposed longer time; see 
Fig. 2B). Since these additional bands could be aberrant lariats or 
degradation products, they were studied with reverse-transcriptase and 
oligonucleotide primers which were complementary to sequences near and 
downstream of the branch-point or 5* splice-site. Band marked as ‘‘1’’ in 
Fig. 2B turned out to be the wild-type lariat that uses the wild-type 5* 
splice-site and branch-point of the β-globin pre-mRNA. Unfortunatelly, we 
are unable to characterize the band marked as ‘‘2’’ in Fig. 2B, since only low 
amounts from band 2 could be purified and there is a high background in 
this area. The product exon1-exon2 seen in Fig. 2 lanes 7 and 8 was 
characterized as the wild-type product as follows: a) in previous works, this 
band was already characterized as the wild-type product in fully active 
extracts (see ref. 8); b) the band named exon1-exon 2 in Fig. 2 lanes 7 and 
8 have the same mobility as the exon1-exon 2 band obtained in fully active 
extracts (compare lanes 7 and 8 with lanes 2 and 3); c) the band has a 
molecular weight of 301 nucleotides that would agree with the exon1-exon 
2 molecular weight and d) the band was assayed by RT-PCR and showed to 
be the exon1-exon 2 product (not shown). The band marked as the 
debranched intron in lanes 7 and 8 was previously analyzed (8) and it was 
assumed to be this product as it was obtained linked to exon1-exon2 
product (see lanes 7 and 8) and had a molecular mass of 126 nucleotides.  
There was a small time-course window, between 15 and 30 min after 
the initiation of the reaction, when yUsnRNPs complemented and completed 
the second step (Fig. 2B, see exon1-exon2 band in lanes 7 and 8). Outside 
this window, no second-step complementation was detected despite the 
presence of yUsnRNPs (Fig. 2B, lanes 6, 9 and 10). This observation 
indicates that the complementation is better achieved during the time lag, 
after 30 min of in vitro reaction. Finally, we want to remark that the ySSA 
activity could be a combination of different yeast UsnRNPs or yeast 
UsnRNPs proteins.  
Due to the fact that very few amounts of yUsnRNPs can be obtained 
from yeast extracts, the assay here described will be more suitable to 
complementation with recombinant yeast proteins than with fractions 
obtained directly from yUsnRNPs. Yeast second-step factors Prp18p, Slu7p 
and Prp17p seem to associate with U5snRNP (3). There is also an uridine 
recognition defect caused by the prp8-101 mutation that inhibites the 
second step splicing reaction (12). Prp8p is the protein that presents a more 
stable association with U5snRNA (3). So far, Prp16p has not been detected 
bound to any UsnRNP, but as Prp16p interacts with Prp17p and Slu7p, it can 
be close or even be loosely bound to the U5snRNP (10). So far, SSF1 has 
been not described to be associated with any yeast UsnRNP particle (11). 
Our very preliminar results indicate that partially purified Slu7p and Prp16p, 
or a combination of Slu7p+Prp16p, do not complement the defective extract 
here described. Any of these factors, or a combination of some of them, 
could be the splicing activity here detected, and the complementation with 
the each recombinant protein would better answer this question.  
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